Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.
about
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutationsCirculating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesPractical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancerTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesInvestigating intratumour heterogeneity by single-cell sequencingDetection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients.Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer.Circulating Tumor DNA as Biomarkers for Cancer Detection.Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient PlasmaPrior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma.Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors?Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients.Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysisRechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer.Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report.Liquid biopsy: monitoring cancer-genetics in the blood.A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistryClinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancerDetection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer.Fool's gold, lost treasures, and the randomized clinical trial.Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.Combination of EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: a meta-analysis.Influence of chemotherapy on EGFR mutation status.Change of SPARC expression after chemotherapy in gastric cancerExon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer.Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status.Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung AdenocarcinomaAutoimmune response to PARP and BRCA1/BRCA2 in cancerLack of epidermal growth factor receptor (EGFR)-activating mutations in triple-negative breast cancer in ChinaComparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung CancerAnalysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients.High-fidelity of non-small cell lung cancer xenograft models derived from bronchoscopy-guided biopsies.Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutationsHepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma.Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitorsAlterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer
P2860
Q21132357-6B9C5930-C58C-47E4-96ED-4FFA71B0AF93Q26775376-E1937564-322F-43E8-ACCB-FD781456F489Q26797297-6780A421-337B-4909-A392-E05858622CD6Q27011355-4B889297-5FB9-4B85-B33C-C29BDE90F65AQ27014117-71609A1D-B785-4AE2-8CFE-4084ECC85151Q27015460-C95F8FFA-473B-4CE8-8F27-150E24481F42Q33582524-D5B9FE3A-BF1A-42FA-B4E3-07EEEAC8EA2EQ33582635-00E2772B-479F-4277-925A-296D82BC8DAFQ33598423-D33618B0-4EAA-4611-A8A4-39FF31CF7ECBQ33632125-F81A9C46-F570-4C50-BBA9-E4C02A0FA779Q33679694-B906F8EF-6AAF-4314-8927-10409D7888E1Q33703063-21AD6D1B-79E7-41BA-B1C0-AEC8911351B9Q33706859-FAAFD4B5-6F44-4C2F-9585-2744B8C17DC6Q34031229-E33EB781-04AC-46E0-BB24-5155491F520FQ34041776-FE203FE6-0BBF-479E-BB96-C72FA42CF845Q34092157-CCA2007B-A7D0-429D-9398-B98C376E0DE9Q34258399-DB9EEE43-EC19-42EB-B12D-E25647FDC197Q34265773-9BB5771A-DB9A-4A46-88D1-51A87365EBD4Q34293223-3B950885-B994-4CE1-A39D-7D61797C0D3CQ34356149-C9ACA890-25D9-44FB-AC54-04865CE25CD9Q34405695-20107BC3-8411-4A6D-8E1D-2D9608C474A3Q34558207-A1FD30D5-F5DD-4FD4-8232-7B388DB50640Q34589493-2BDAC544-9064-4065-A277-C9C319AEDBDBQ34669260-3540B974-9774-4108-AE2D-99C289DDA282Q35034044-88DE6406-5D05-481D-8F8A-ED4065C14A5CQ35043675-1C5149F7-F52F-4459-A079-3EF870FF7DDDQ35200458-4FE09414-71DD-4326-B3B0-D57219AE0B37Q35252935-5245C540-5A82-49BE-B9AB-977F816B71F2Q35669012-27102198-30A6-448D-B633-0FED2322B812Q35681695-0CABC25C-7E59-45F7-B861-1D7E242D2A52Q35791225-19527912-2922-4DC5-9B99-98D76B68A417Q35793861-FDAA8DEC-C059-4B06-A24C-E340310B284EQ35986006-404A0BB7-CEB6-41B0-B97E-2862B8DFF751Q36148697-83E7796E-1BB6-4216-9116-DF7409BC0E4DQ36439434-50DACABC-6A03-40CD-BC45-8FB5AF22795DQ36477716-817B9900-1879-4B7A-A00B-81C4353E6A53Q36477762-84D03F29-5507-4183-A0ED-6E1F2017C449Q36525517-82C7ED2F-1957-45BF-9E78-AD3D0D7534DDQ36540405-10098DDD-6A86-4863-AFB4-EFFCE47BD26BQ36669872-6BEAFB64-BE53-4782-9735-651313FE29FC
P2860
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 July 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Influence of chemotherapy on E ...... th non-small-cell lung cancer.
@en
Influence of chemotherapy on E ...... th non-small-cell lung cancer.
@nl
type
label
Influence of chemotherapy on E ...... th non-small-cell lung cancer.
@en
Influence of chemotherapy on E ...... th non-small-cell lung cancer.
@nl
prefLabel
Influence of chemotherapy on E ...... th non-small-cell lung cancer.
@en
Influence of chemotherapy on E ...... th non-small-cell lung cancer.
@nl
P2093
P2860
P356
P1476
Influence of chemotherapy on E ...... ith non-small-cell lung cancer
@en
P2093
J Jack Lee
Jianchun Duan
Keneng Chen
Qinghua Zhou
P2860
P304
P356
10.1200/JCO.2011.39.3744
P407
P50
P577
2012-07-23T00:00:00Z